论文题目：Is better hypertension management buyable? - Evidence on hypertension treatment, education and control from China Health and Retirement Longitudinal Study
摘要：In 2009, China launched a major healthcare reform that quadrupled government funding for health and pledged to provide equal access to basic health care for all citizens, with reasonable quality and financial risk protection. However, there are still widespread gaps in universal health coverage in China, such as the quality of care, control of non-communicable diseases, delivery efficiency, health expenditure control and public satisfaction. One of the challenges that universal health coverage in China faces is the poor performance in control of risk factors such as hypertension. In China, hypertension, with high and increasing prevalence and as a leading cause of premature death, has become a serious public health concern. We study the causal effect of government health expenditure on hypertension management using data collected in three waves of the China Health and Retirement Longitudinal Study (CHARLS) in 2011, 2013, and 2015. In this study, we use prefecture-level government health expenditure as the measure of public resources invested in hypertension management. Our analysis suggests that raise of government health expenditure in the new healthcare reform since 2009 cause a better hypertension management on medication treatment and patient education for urban males in China but not in other groups.
黄志勇，瑞士洛桑大学经济学博士、西南财经大学公共管理学院副教授（已长聘）、北京大学中国卫生经济研究中心访问研究员、西南财经大学健康发展研究院副院长、四川省药学会药物经济委员会委员、四川省医保局医疗保障专家库成员。在《Assessment》、《Community Mental Health J》、《Finance Research Letters》等SSCI期刊发表论文6篇，主持国家自然科学基金青年项目1项，作为副主编参编“十三五”国家重点图书出版规划项目1项。